DTC-IN003

DTC-IN003 is an investigational **intranasal COVID-19 vaccine candidate** from Defence Therapeutics designed as a **transmission-blocking** formulation intended to stop infection at the mucosal entry site rather than primarily reduce downstream disease pathophysiology. Public company materials describe it as a **protein-based vaccine** administered intranasally with a specialized adjuvant for nasal delivery, and report induction of **mucosal IgA** together with **systemic immunity**. It appears to leverage Defence Therapeutics' **Accum** intracellular delivery platform, which the company says is intended to enhance antigen processing and presentation by promoting endosomal escape and cytosolic delivery of biologic cargo. Based on the available public information, DTC-IN003 remained in **preclinical development** for COVID-19, and specific antigen composition, exact molecular target details, and any later clinical advancement have not been clearly disclosed.